In vitro–expanded antigen-specific regulatory T cells suppress autoimmune diabetes

Q Tang, KJ Henriksen, M Bi, EB Finger, G Szot… - The Journal of …, 2004 - rupress.org
Q Tang, KJ Henriksen, M Bi, EB Finger, G Szot, J Ye, EL Masteller, H McDevitt, M Bonyhadi…
The Journal of experimental medicine, 2004rupress.org
The low number of CD4+ CD25+ regulatory T cells (Tregs), their anergic phenotype, and
diverse antigen specificity present major challenges to harnessing this potent tolerogenic
population to treat autoimmunity and transplant rejection. In this study, we describe a robust
method to expand antigen-specific Tregs from autoimmune-prone nonobese diabetic mice.
Purified CD4+ CD25+ Tregs were expanded up to 200-fold in less than 2 wk in vitro using a
combination of anti-CD3, anti-CD28, and interleukin 2. The expanded Tregs express a …
The low number of CD4+ CD25+ regulatory T cells (Tregs), their anergic phenotype, and diverse antigen specificity present major challenges to harnessing this potent tolerogenic population to treat autoimmunity and transplant rejection. In this study, we describe a robust method to expand antigen-specific Tregs from autoimmune-prone nonobese diabetic mice. Purified CD4+ CD25+ Tregs were expanded up to 200-fold in less than 2 wk in vitro using a combination of anti-CD3, anti-CD28, and interleukin 2. The expanded Tregs express a classical cell surface phenotype and function both in vitro and in vivo to suppress effector T cell functions. Most significantly, small numbers of antigen-specific Tregs can reverse diabetes after disease onset, suggesting a novel approach to cellular immunotherapy for autoimmunity.
rupress.org